THE SPECIFIC ISSUES OF ELDERLY PEOPLE VACCINATION

DOI: https://doi.org/10.29296/25877305-2019-06-05
Download full text PDF
Issue: 
6
Year: 
2019

L. Titareva, Candidate of Medical Sciences Kursk State Medical University

Currently, despite the extensive experience of countries and health professionals in vaccination fields, there are many unresolved issues. This is especially true of vaccination in elderly people. Today there is a need to develop clear vaccination programs at all levels, especially at the state level, taking into account all the features of the elderly population. The author also presents specific issues of vaccination, such as vaccination for influenza and Herpes Zoster prevention, pneumococcal vaccination and others. The question of optimization of vaccination taking into account its positive impact on the prognosis, quality and life expectancy is discussed. Vaccination coverage, unfortunately, remains low, as does the degree to which the population as a whole is convinced of the need for vaccination.
Keywords: 
vaccination
elderly age
prevention

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

References: 
  1. Bader M. Immunization for the Elderly // Am. J. Med. Sci. – 2007; 334 (6): 481–6.
  2. Doherty M., Connolly M., Del Giudice G. et al. Vaccination programs for older adults in an era of demographic change // Eur. Geriatric Med. – 2018; 9 (3): 289–300. DOI: 10.1007/s41999-018-0040-8.
  3. Triglav T., Poljak M. Vaccination indications and limits in the elderly // Acta Dermatovenerol. Alp. Pannonica Adriat. – 2013; 22 (3): 65–70.
  4. Jefferson T., Rivetti D., Rudin M. et al. Efficacy and effectiveness of influenza vaccines in elderly people: a systematic review // Lancet. – 2005; 366: 1165–74.
  5. McElhaney J., Beran J., Devaster J. et al. AS03-adjuvanted versus non-adjuvanted inactivated trivalent influenza vaccine against seasonal influenza in elderly people: a phase 3 randomised trial // Lancet Infect. Dis. – 2013; 13: 485–96.
  6. Centers for Disease Control and Prevention (CDC). Recommended adult immunization schedule: United States, October 2006 – September 2007 // MMWR Morb Mortal Wkly Rep. – 2006; 55: Q1–4.
  7. Lexau C., Lynfield R., Danila R. et al. Bacterial Core Surveillance Team: changing epidemiology of invasive pneumococcal disease among older adults in the era of pediatric pneumococcal conjugate vaccine // JAMA. – 2005; 294: 2043–51.
  8. Dworkin R., Johnson R., Breuer J. Recommendations for the management of herpes zoster // Clin. Infect. Dis. – 2007; 44: S1–26.
  9. Rothberg M., Virapongse A., Smith K. Cost-effectiveness of a vaccine to prevent herpes zoster and postherpetic neuralgia in older adults // Clin. Infect. Dis. – 2007; 44: 1280–8.
  10. Kretsinger K., Broder K., Cortese M. et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine // MMWR Morb. Mortal. Wkly Rep. – 2006; 55: 1–33.
  11. Centers for Disease Control and Prevention. Black C., Yankey D., Kolasa M. National, state and local area vaccination coverage among children aged 19–35 months – United States, 2012 // MMWR. – 2013; 62: 733–7. https://www.cdc.gov/mmwr/previ ew/mmwrh tml/mm623 6a1.htm